OPNT - オピアント・ファ―マシュ―ティカルズ (Opiant Pharmaceuticals Inc.) オピアント・ファ―マシュ―ティカルズ

 OPNTのチャート


 OPNTの企業情報

symbol OPNT
会社名 Opiant Pharmaceuticals Inc (オピアント・ファ―マシュ―ティカルズ)
分野(sector) Basic Industries   素材
産業(industry) Precious Metals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Opiant Pharmaceuticals Inc. formerly Lightlake Therapeutics Inc. is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray a treatment to reverse opioid overdoses which was conceived licensed developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED) a treatment for Bulimia Nervosa (BN) a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.   オピアント・ファ―マシュ―ティカルズは米国の専門製薬会社。主に薬物使用、中毒、摂食障害に対する治療法の開発に従事する。オピオイド系鎮痛剤の過剰摂取をリバ―スさせるナロキソン塩酸塩「NARCAN」鼻腔用スプレ―を開発。同社製品候補には過食症治療薬、コカイン使用障害治療薬、ヘロインワクチンが含まれる。本社所在地はカリフォルニア州サンタ・モニカ。   Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
本社所在地 201 Santa Monica Boulevard Suite 500 Santa Monica CA 90401 USA
代表者氏名 Michael J. Sinclair マイケル・シンクレア
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 310-598-5410
設立年月日 38504
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 14人
url www.lightlaketherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/opnt
adr_tso
EBITDA EBITDA(百万ドル) -9.08382
終値(lastsale) 17.27
時価総額(marketcap) 63701206.69
時価総額 時価総額(百万ドル) 58.81564
売上高 売上高(百万ドル) 16.61532
企業価値(EV) 企業価値(EV)(百万ドル) 47.57064
当期純利益 当期純利益(百万ドル) -9.36162
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Opiant Pharmaceuticals Inc revenues totaled $4.9M. Net loss totaled to $10.7M. Results are not comparable due to year end change.

 OPNTのテクニカル分析


 OPNTのニュース

   Opiant Jumps on Opioid Overdose Treatment Results  2021/07/07 19:01:24 The Street
Opiant Pharmaceuticals climbs as the company reports positive results for its nasal spray treatment for opioid overdoses.
   Opiant Jumps on Results  2021/07/07 14:17:00 Baystreet Canada
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) shares rose sharply Wednesday after the company disclosed positive top-line results of confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, a novel investigational treatment for opioid overdose. The Santa Monica-based Opiant says the study was conducted in 68 healthy subjects and compared OPNT003, nalmefene hydrochloride nasal spray, 3 mg, ("nasal nalmefene"), with an intramuscular nalmefene hydrochloride injection, 1 mg, which was the comparator previously agreed upon with the U.S. Food and Drug Administration. According to an initial analysis, the top-line data demonstrated that nasal nalmefene achieved significantly higher plasma concentrations compared to an intramuscular injection (p<0.0001). The time for nasal nalmefene to achieve maximum plasma concentrations (T max ) was consistent with data from the previously completed pilot study (~15 minutes). The maximum plasma concentration (C max ) was higher than observed in the pilot study, and the plasma half-life of nasal nalmefene (~11 hours) was consistent with reported values following other routes (oral and parenteral) of administration.
   Opiant reports topline data from confirmatory PK study of OPNT-003 for opioid overdose  2021/07/07 13:58:04 BioWorld
   Opiant shares rise on OPNT003 opioid overdose study results  2021/07/06 20:05:32 Seeking Alpha
   Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose  2021/07/06 20:01:00 Intrado Digital Media
SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (PK) study for OPNT003, nasal nalmefene, for opioid overdose.
   Opiant Pharma's Starts Dosing In Nasal Nalmefene Comparison Study For Remifentanil-Related Respiratory Depression  2021/04/06 10:22:23 Benzinga
Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone. The
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment  2020/10/29 20:05:00 GlobeNewswire
Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device Reinforces Opiant’s…
   Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020  2020/10/27 20:01:00 GlobeNewswire
SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company…
   Opiant Pharma's Starts Dosing In Nasal Nalmefene Comparison Study For Remifentanil-Related Respiratory Depression  2021/04/06 10:22:23 Benzinga
Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone. The
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment  2020/10/29 20:05:00 GlobeNewswire
Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device Reinforces Opiant’s…
   Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020  2020/10/27 20:01:00 GlobeNewswire
SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company…

 関連キーワード  (医薬品 米国株 オピアント・ファ―マシュ―ティカルズ OPNT Opiant Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)